Cancer Gene Therapy
Reports on cancer gene therapy findings from University of Texas provide new insights
Published in Cancer Weekly, February 3rd, 2009
"RB94, which lacks the N-terminal 112 amino-acid residues of the full-length retinoblastoma protein (RB110) is a more potent inhibitor of cancer cell growth than RB110, being cytotoxic to all cancer cell lines studied, independent of their genetic abnormalities. Although we initially thought RB94-induced cell death was caspase-dependent, such caspase activation now appears to be a late event," scientists writing in the journal Cancer Gene Therapy report.
"Cells that remained attached 48 h after transduction with Ad-RB94 showed, among other changes, nuclear enlargement, peripheral nuclear chromatin condensation and often micronucleation. In addition, the cells...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-02-03)
More Articles from Cancer Weekly
- Biopsy
Data from University of Virginia provide new insights into biopsy - Cancer Gene Therapy
New cancer gene therapy research has been reported by scientists at Nanjing Medical University - Cancer Gene Therapy
Reports from Fudan University describe recent advances in cancer gene therapy - Cancer Gene Therapy
Reports summarize cancer gene therapy study results from Xuzhou Medical College, Medical College - Cancer Gene Therapy
Researchers from INSERM publish new studies and findings in the area of cancer gene therapy - Cancer Gene Therapy
Researchers from Okayama University provide details of new studies and findings in the area of cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
